Cargando…

Children with hemodynamically significant congenital heart disease can be identified through population-based registers

BACKGROUND: Epidemiological research is facilitated in Sweden by a history of national health care registers, making large unselected national cohort studies possible. However, for complex clinical populations, such as children with congenital heart disease (CHD), register-based studies are challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Gunnar, Hærskjold, Ann, Stensballe, Lone Graff, Kieler, Helle, Linder, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315391/
https://www.ncbi.nlm.nih.gov/pubmed/25657596
http://dx.doi.org/10.2147/CLEP.S73358
_version_ 1782355463759724544
author Bergman, Gunnar
Hærskjold, Ann
Stensballe, Lone Graff
Kieler, Helle
Linder, Marie
author_facet Bergman, Gunnar
Hærskjold, Ann
Stensballe, Lone Graff
Kieler, Helle
Linder, Marie
author_sort Bergman, Gunnar
collection PubMed
description BACKGROUND: Epidemiological research is facilitated in Sweden by a history of national health care registers, making large unselected national cohort studies possible. However, for complex clinical populations, such as children with congenital heart disease (CHD), register-based studies are challenged by registration limitations. For example, the diagnostic code system International Classification of Diseases, 10th version (ICD-10) does not indicate the clinical significance of abnormalities, therefore may be of limited use if used as the sole parameter in epidemiological research. Palivizumab is indicated as a prophylactic treatment against respiratory syncytial virus infections in children with hemodynamically significant CHD. AIM: The aim of the study reported here was to develop and validate an algorithm to identify children with hemodynamically significant CHD according to recommendations for palivizumab prophylaxis in register-based research. METHODS: By using a strategy of combining criteria for age at diagnosis, diagnostic codes, surgical procedure codes, and dispensing records, we created an algorithm to define the specific cases with hemodynamically significant CHD in which palivizumab could be advocated according to recommendations. RESULTS: The algorithm identified 928 children with hemodynamically significant CHD in the Swedish birth cohort born July 1, 2005 to December 31, 2010. A sensitivity (95% confidence interval) of 80% (70–88) for the algorithm was found by analyzing 121 children identified through local hospital data who were treated with palivizumab within a defined region and study period. The positive predictive value was estimated by medical record review in a random sample of 34 cases identified by the algorithm. In 79% (62–91) of these cases, the children were regarded as having hemodynamically significant CHD according to the recommendations for treatment with palivizumab. CONCLUSION: It was possible to identify a subgroup of children with hemodynamically significant CHD using an epidemiological approach and an algorithm with high validity. Our results will enable well-powered national cohort studies of individuals with complex clinical conditions such as hemodynamically significant CHD.
format Online
Article
Text
id pubmed-4315391
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43153912015-02-05 Children with hemodynamically significant congenital heart disease can be identified through population-based registers Bergman, Gunnar Hærskjold, Ann Stensballe, Lone Graff Kieler, Helle Linder, Marie Clin Epidemiol Original Research BACKGROUND: Epidemiological research is facilitated in Sweden by a history of national health care registers, making large unselected national cohort studies possible. However, for complex clinical populations, such as children with congenital heart disease (CHD), register-based studies are challenged by registration limitations. For example, the diagnostic code system International Classification of Diseases, 10th version (ICD-10) does not indicate the clinical significance of abnormalities, therefore may be of limited use if used as the sole parameter in epidemiological research. Palivizumab is indicated as a prophylactic treatment against respiratory syncytial virus infections in children with hemodynamically significant CHD. AIM: The aim of the study reported here was to develop and validate an algorithm to identify children with hemodynamically significant CHD according to recommendations for palivizumab prophylaxis in register-based research. METHODS: By using a strategy of combining criteria for age at diagnosis, diagnostic codes, surgical procedure codes, and dispensing records, we created an algorithm to define the specific cases with hemodynamically significant CHD in which palivizumab could be advocated according to recommendations. RESULTS: The algorithm identified 928 children with hemodynamically significant CHD in the Swedish birth cohort born July 1, 2005 to December 31, 2010. A sensitivity (95% confidence interval) of 80% (70–88) for the algorithm was found by analyzing 121 children identified through local hospital data who were treated with palivizumab within a defined region and study period. The positive predictive value was estimated by medical record review in a random sample of 34 cases identified by the algorithm. In 79% (62–91) of these cases, the children were regarded as having hemodynamically significant CHD according to the recommendations for treatment with palivizumab. CONCLUSION: It was possible to identify a subgroup of children with hemodynamically significant CHD using an epidemiological approach and an algorithm with high validity. Our results will enable well-powered national cohort studies of individuals with complex clinical conditions such as hemodynamically significant CHD. Dove Medical Press 2015-01-23 /pmc/articles/PMC4315391/ /pubmed/25657596 http://dx.doi.org/10.2147/CLEP.S73358 Text en © 2015 Bergman et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Bergman, Gunnar
Hærskjold, Ann
Stensballe, Lone Graff
Kieler, Helle
Linder, Marie
Children with hemodynamically significant congenital heart disease can be identified through population-based registers
title Children with hemodynamically significant congenital heart disease can be identified through population-based registers
title_full Children with hemodynamically significant congenital heart disease can be identified through population-based registers
title_fullStr Children with hemodynamically significant congenital heart disease can be identified through population-based registers
title_full_unstemmed Children with hemodynamically significant congenital heart disease can be identified through population-based registers
title_short Children with hemodynamically significant congenital heart disease can be identified through population-based registers
title_sort children with hemodynamically significant congenital heart disease can be identified through population-based registers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315391/
https://www.ncbi.nlm.nih.gov/pubmed/25657596
http://dx.doi.org/10.2147/CLEP.S73358
work_keys_str_mv AT bergmangunnar childrenwithhemodynamicallysignificantcongenitalheartdiseasecanbeidentifiedthroughpopulationbasedregisters
AT hærskjoldann childrenwithhemodynamicallysignificantcongenitalheartdiseasecanbeidentifiedthroughpopulationbasedregisters
AT stensballelonegraff childrenwithhemodynamicallysignificantcongenitalheartdiseasecanbeidentifiedthroughpopulationbasedregisters
AT kielerhelle childrenwithhemodynamicallysignificantcongenitalheartdiseasecanbeidentifiedthroughpopulationbasedregisters
AT lindermarie childrenwithhemodynamicallysignificantcongenitalheartdiseasecanbeidentifiedthroughpopulationbasedregisters